Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
NCT03607422Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of upadacitinib in atopic dermatitis (AD), sponsored by AbbVie Inc.. Started Jul 2018; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03607422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03607422.